All In Biotech

NDA 215866 · Eli Lilly and CO

Mounjaro

Tirzepatide · Subcutaneous · Glucose-dependent Insulinotropic Polypeptide Receptor Agonist; GLP-1 Receptor Agonist

NovelPriority review

CDER novel approval, May 13, 2022: To improve blood sugar control in diabetes, in addition to diet and exercise

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 13, 2022

Approved uses

4

Original approval plus efficacy supplements

Registered trials

242

59 Phase 3, 94 recruiting

FAERS reports

100,728

27,362 serious, 887 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin...

What it is approved for

From the label in effect Aug 27, 2026.

MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

Mechanism: Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

24 products under this application
  • MOUNJARO · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO KWIKPEN · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tirzepatide" as an intervention, any sponsor and status, largest first.

All 242 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • incorrect dose administered17,484
  • nausea10,241
  • injection site pain9,528
  • off label use8,262
  • diarrhoea6,368
  • vomiting5,525
  • extra dose administered5,273
  • constipation3,915
  • injection site haemorrhage3,644
  • product dose omission issue3,451
  • injection site erythema3,219
  • blood glucose increased3,088

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20166
20176
20183
201924
202030
202132
20225,039
202320,764
202422,632
202531,711
202620,481

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mounjaro (Tirzepatide)

2024 spending

$6.34B

Beneficiaries

894,581

5,105,397 claims

Per beneficiary

$7,084

$511.63 per unit

View as table
YearSpending
2020$0
2021$0
2022$144,035,152
2023$2,361,384,157
2024$6,336,942,641

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 373 on PubMed

Sponsor: Eli Lilly · Also marketed as Mounjaro Kwikpen, Mounjaro (Autoinjector)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.